Get started
Author

Ankur Srivastava

Observed names: A Srivastava, A. Srivastava, A., Srivastava, Srivastava, A, Srivastava, Ankur
Observed institutions: North Bristol NHS Trust, Royal Free London NHS Foundation Trust, Western General Hospital, The Royal Free Hospital, Southmead Hospital, University College London
ORCID: 0000-0001-7902-3712
Observed ORCID: 0000-0001-7902-3712
OpenAlex ID: A5047165583
Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease
2019 · Ankur Srivastava, Ruth Gailer, et al. · Journal of Hepatology · 471
PDF
Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C
2020 · Sudeep Tanwar, Freya Rhodes, et al. · World Journal of Gastroenterology · 266
Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease
2019 · Ankur Srivastava, Simcha Jong, et al. · BMC Gastroenterology · 139
PDF
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
2022 · Simeng Lin, Nicholas A. Kennedy, et al. · Nature Communications · 105
PDF
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group
2022 · Stuart McPherson, Matthew J Armstrong, et al. · The Lancet. Gastroenterology & hepatology · 95
PDF
Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: Diagnostic accuracy and cost analysis
2019 · Catriona Crossan, Avik Majumdar, et al. · Liver International · 88
PDF
Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C ( CH ‐C) patients: an economic model from five European countries
2015 · Z. Younossi, A. Brown, et al. · Journal of Viral Hepatitis · 57
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
2022 · Zhigang Liu, Kaixing Le, et al. · The Lancet. Gastroenterology & hepatology · 36
Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment
2020 · Ahmed Hussain, Preya J Patel, et al. · Clinical Medicine · 35
PDF
Quality standards for the management of alcohol-related liver disease: consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology ARLD special interest group
2023 · Richard Parker, Michael Allison, et al. · BMJ Open Gastroenterology · 18
PDF
Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy
2016 · Sudeep Tanwar, Paul M. Trembling, et al. · European Journal of Gastroenterology & Hepatology · 13
Regional variation in characteristics of patients with decompensated cirrhosis admitted to hospitals in the UK
2023 · Oliver D Tavabie, Kushala WM Abeysekera, et al. · The Lancet. Gastroenterology & hepatology · 11
A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of chronic liver disease
2019 · Preya Janubhai Patel, Declan Connoley, et al. · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · 11
Exploring changing attitudes to non-invasive liver fibrosis tests in secondary care pathways: comparison of two national surveys
2023 · Kushala W M Abeysekera, Ankur Srivastava, et al. · Frontline Gastroenterology · 9
PDF
Risk-adjusted survival in liver transplant patients assessed and managed by a non-transplanting centre: South West Liver Unit experience
2019 · Benjamin Charles Norton, Ankur Srivastava, et al. · Frontline Gastroenterology · 8
Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study
2017 · On behalf of the Joint UK CHIC and liver transplant advisory group, Charlotte Warren-Gash, et al. · Infection · 8
PDF
Current Surveillance Strategy Is Less Effective for Detecting Early-Stage Hepatocellular Carcinoma in Patients with Non-Viral and Non-Cirrhotic Liver Disease
2025 · Jessica Spiers, Wenhao Li, et al. · Liver Cancer · 7
Twitter debate: controversies in liver transplantation
2021 · Oliver D Tavabie, Ankur Srivastava, et al. · Frontline Gastroenterology · 7
Optimising referral pathways for patients with non-alcoholic fatty liver disease in the UK
2021 · Alexander Boyd, Ankur Srivastava, et al. · British Journal of Healthcare Management · 5
Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease
2020 · Sudeep Tanwar, Ankur Srivastava, et al. · Journal of Hepatology · 5
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus
2026 · Jeremy F Cobbold, Hamish Miller, et al. · The Lancet. Gastroenterology & hepatology · 3
From O’Shaughnessy to opportunity: innovating Hepatology Trials in the UK
2024 · Oliver D Tavabie, Yvanne Enever, et al. · Frontline Gastroenterology · 3
PDF
Referral pathways for patients with non-alcoholic fatty liver disease based on non-invasive fibrosis tests: diagnostic accuracy and cost analysis of a two-tier approach
2017 · A. Majumdar, C. Crossan, et al. · Journal of Hepatology · 3
ELF (TM) predicts clinical outcomes in liver disease.
2015 · Hogan, BJ, O'Beirne, J, et al. · UCL Discovery (University College London) · 3
Reply to: “FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)”
2020 · Emmanuel A. Tsochatzis, Ankur Srivastava, et al. · Journal of Hepatology · 2
PDF
Works count: 55
Citation count: 1,416
H-index: 11
I10-index: 13
Year
Topic
Type